- Home
- KRRO vs CRVS Comparison
KRRO vs CRVS Comparison
Compare KRRO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- CRVS
- Stock Information
- Founded
- KRRO 2014
- CRVS 2014
- Country
- KRRO United States
- CRVS United States
- Employees
- KRRO N/A
- CRVS N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- CRVS Health Care
- Exchange
- KRRO Nasdaq
- CRVS Nasdaq
- Market Cap
- KRRO 209.6M
- CRVS 206.5M
- IPO Year
- KRRO 2019
- CRVS 2016
- Fundamental
- Price
- KRRO $15.56
- CRVS $4.43
- Analyst Decision
- KRRO Strong Buy
- CRVS Strong Buy
- Analyst Count
- KRRO 7
- CRVS 3
- Target Price
- KRRO $90.67
- CRVS $16.33
- AVG Volume (30 Days)
- KRRO 102.4K
- CRVS 1.4M
- Earning Date
- KRRO 05-07-2025
- CRVS 05-08-2025
- Dividend Yield
- KRRO N/A
- CRVS N/A
- EPS Growth
- KRRO N/A
- CRVS N/A
- EPS
- KRRO N/A
- CRVS N/A
- Revenue
- KRRO $4,821,000.00
- CRVS N/A
- Revenue This Year
- KRRO N/A
- CRVS N/A
- Revenue Next Year
- KRRO $55.56
- CRVS N/A
- P/E Ratio
- KRRO N/A
- CRVS N/A
- Revenue Growth
- KRRO N/A
- CRVS N/A
- 52 Week Low
- KRRO $11.13
- CRVS $1.75
- 52 Week High
- KRRO $98.00
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- KRRO 45.62
- CRVS 68.59
- Support Level
- KRRO $13.40
- CRVS $3.17
- Resistance Level
- KRRO $22.15
- CRVS $3.71
- Average True Range (ATR)
- KRRO 2.47
- CRVS 0.23
- MACD
- KRRO 0.07
- CRVS 0.08
- Stochastic Oscillator
- KRRO 24.69
- CRVS 95.47
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).